SHIRE PLC: Shire reaches agreement in principle with US Government

SHIRE PLC: Shire reaches agreement in principle with US Government
Shire reaches agreement in principle with U.S. Government 
Philadelphia, PA, United States - February 1, 2013 - Shire plc (LSE: SHP,
NASDAQ: SHPG), today announced that it has reached an agreement in principle to
resolve the previously disclosed civil investigation into Shire's U.S. sales
and marketing practices relating to ADDERALL XR®, VYVANSE® and DAYTRANA®. 
The investigation was led by the U.S. Attorney's Office for the Eastern
District of Pennsylvania, and Shire disclosed the investigation in 2009. The
agreement also addresses sales and marketing practices relating to LIALDA® and
PENTASA® pursuant to a subsequent voluntary disclosure made by Shire. 
Shire cooperated with the U.S. Government throughout the process that led to
this agreement in principle. Shire has recorded a $57.5M charge in the fourth
quarter of 2012, comprised of the agreement in principle amount, interest and
The agreement in principle is subject to change until this matter is finally
resolved.  Discussions between Shire and the U.S. Government are ongoing to
establish a final resolution to the investigation. 
For further information please contact: 
Investor Relations                                                              
Eric Rojas                         +1 781 482 0999    
Sarah Elton-Farr               +44 1256 894157    
Jessica Mann (Corporate)            +44 1256 894 280   
Notes to editors 
Shire enables people with life-altering conditions to lead better lives. 
Through our deep understanding of patients' needs, we develop and provide
healthcare in the areas of: 
* Behavioral Health and Gastro Intestinal conditions 

      * Rare Diseases
      * Regenerative Medicine
    as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value for
patients, physicians, policymakers, payors and our shareholders.


Statements included herein that are not historical facts are forward-looking
statements. Such forward-looking statements involve a number of risks and
uncertainties and are subject to change at any time. In the event such risks or
uncertainties materialize, the Company's results could be materially adversely
affected. The risks and uncertainties include, but are not limited to, risks
associated with: the inherent uncertainty of research, development, approval,
reimbursement, manufacturing and commercialization of the Company's Specialty
Pharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, as
well as the ability to secure new products for commercialization and/or
development; government regulation of the Company's products; the Company's
ability to manufacture its products in sufficient quantities to meet demand;
the impact of competitive therapies on the Company's products; the Company's
ability to register, maintain and enforce patents and other intellectual
property rights relating to its products; the Company's ability to obtain and
maintain government and other third-party reimbursement for its products; and
other risks and uncertainties detailed from time to time in the Company's
filings with the Securities and Exchange Commission.

DAYTRANA® is a trademark of Noven Pharmaceutical Inc.

Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release                                     

-0- Feb/01/2013 17:00 GMT